rethinkTHC Search
Menu
Study breakdown

CBD Shows Antitumor Effects Against Bone Cancer by Targeting an Inflammatory Pathway

PreclinicalPreliminary evidence
The takeaway

CBD suppressed osteosarcoma cell growth and tumor formation in mice by directly binding to NF-kB and disrupting the TNF-alpha/NF-kB/CCL5 inflammatory signaling axis.

Cancer researchers, oncologists following cannabinoid research, and anyone interested in CBD's potential anti-cancer mechanisms beyond anecdotal claims.

What the researchers found

CBD directly binds the NF-kB subunit p65, disrupting a positive feedback loop between NF-kB and CCL5 that drives osteosarcoma inflammation and proliferation. This was validated in both cell culture and mouse tumor models.

Why it matters

Osteosarcoma is an aggressive bone cancer with limited treatment options. Identifying that CBD targets a specific inflammatory pathway provides a mechanistic rationale for further investigation, beyond general anti-cancer claims.

The numbers in context

CBD suppressed proliferation (EdU assay), migration, and invasion in cell culture. Inhibited xenograft tumor growth in vivo. Molecular binding to p65 confirmed by four complementary methods.

How the study worked

Comprehensive preclinical study using cell viability assays, functional assays (proliferation, migration, invasion), mouse xenograft tumors, network pharmacology, RNA-seq, and molecular binding confirmation (CETSA, SPR, ITC, molecular docking).

What this study cannot tell us

Preclinical only — mouse xenograft models don't fully replicate human bone cancer. CBD concentrations used may not be achievable in human patients. Single cancer type studied.

How to read the evidence

Thorough preclinical investigation with multiple validation methods, but remains far from clinical application.

When this study was published

Recent study providing the first evidence of CBD targeting the TNF-alpha/NF-kB/CCL5 axis in osteosarcoma.

The bigger picture

Anti-cancer claims for CBD are common but often lack mechanistic evidence. This study provides the first detailed molecular mechanism for CBD's effects on osteosarcoma, moving beyond 'CBD kills cancer cells' to identifying exactly how and where it acts.

Questions still open

  • Could CBD enhance existing osteosarcoma treatments as a combination therapy? Would the NF-kB-targeting mechanism apply to other cancers driven by this inflammatory pathway?

Common questions

Can CBD treat bone cancer?
This preclinical study shows CBD can inhibit osteosarcoma cells and tumors in mice by targeting a specific inflammatory pathway. However, human clinical trials would be needed before making any treatment claims.
How does CBD target cancer cells?
In this study, CBD directly binds to a protein called p65 (part of NF-kB), disrupting an inflammatory signaling loop that cancer cells use to grow and spread.

Read the original research

Antitumor effects of cannabidiol (CBD) on osteosarcoma by targeting TNF-α/NF-κB/CCL5 signaling axis.

Phytomedicine : international journal of phytotherapy and phytopharmacology, 145, 157066

Citation

Yang, Fan; Duan, Shuqin; Liu, Jingwei; An, Zhechao; Liu, Wangyang; Wang, Xinyue; Zhang, Tingting; Liu, Mingyu; Li, Fengda; Wu, Wei; Liu, Yingzhe; Tang, Jianyong; Wang, Xiaojuan; Xu, Wenhui; Qi, Wenyi; Liu, Yunhe; Li, Liangliang; Li, Yuan; Liu, Xin; Yang, Baofeng; Zhang, Zheng; Wang, Li; Yang, Lei. (2025). Antitumor effects of cannabidiol (CBD) on osteosarcoma by targeting TNF-α/NF-κB/CCL5 signaling axis.. Phytomedicine : international journal of phytotherapy and phytopharmacology, 145, 157066. https://doi.org/10.1016/j.phymed.2025.157066

Explore the wider topic